Chemistry:11-Hydroxy-THC

From HandWiki
Short description: Chemical compound
11-Hydroxy-THC
11-OH-THC.svg
11-Hydroxy-THC molecule
Clinical data
Drug classCannabinoid
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H30O3
Molar mass330.468 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

11-Hydroxy-Δ9-tetrahydrocannabinol (11-OH-Δ9-THC, alternatively numbered as 7-OH-Δ1-THC), usually referred to as 11-hydroxy-THC is the main active metabolite of tetrahydrocannabinol (THC), which is formed in the body after Δ9-THC is consumed.[1][2]

After cannabis consumption, THC is metabolized inside the body by cytochrome P450 enzymes such as CYP2C9 and CYP3A4 into 11-hydroxy-THC and then further metabolized by the dehydrogenase and CYP2C9 enzyme to form 11-nor-9-carboxy-THC (THC-COOH) which is inactive at the CB1 receptors;[2] and further glucuronidated to form 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide (Δ9-THC-COOH-glu)[3] where it is excreted in both feces and urine.[4] Both compounds, along with THC, can be assayed in drug tests.[1]

11-hydroxy-THC can be formed after consumption of THC from inhalation (vaping, smoking) and oral (by mouth, edible, sublingual) use, although levels of 11-hydroxy-THC are typically higher when eaten compared to inhalation.[5][6]

Pharmacology

Like Δ9-THC, 11-hydroxy-THC is a partial agonist at the cannabinoid receptor CB1 with significantly higher binding affinity (Ki = 0.37 nM compared to Δ9-THC Ki = 35 nM).[7] With respect to cAMP inhibition at CB1 it displays a similar efficacy to that of Δ9-THC (EC50 = 11 nM vs. EC50 = 5.2 nM, respectively), but a lower maximum response (Emax = 28% vs. Emax = 70%).[7]

Research

In an in vitro analysis by the University of Rhode Island on cannabinoids it was found that 11-OH-Δ9-THC had the 3rd highest 3C-like protease inhibitor activity against COVID-19 out of all the cannabinoids tested within that study but not as high as the antiviral drug GC376 (56% 11-OH-Δ9-THC vs 100% GC376).[8]

See also

References

  1. 1.0 1.1 "Bioanalytical procedures for determination of drugs of abuse in blood". Analytical and Bioanalytical Chemistry 388 (7): 1415–1435. August 2007. doi:10.1007/s00216-007-1271-6. PMID 17468860. 
  2. 2.0 2.1 "Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol". Cannabinoids. Handbook of Experimental Pharmacology. 168. 2005. pp. 657–690. doi:10.1007/3-540-26573-2_23. ISBN 3-540-22565-X. 
  3. "Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review". Drug Metabolism Reviews 46 (1): 86–95. February 2014. doi:10.3109/03602532.2013.849268. PMID 24160757. https://zenodo.org/record/1093138. 
  4. "Pharmacokinetics and pharmacodynamics of cannabinoids". Clinical Pharmacokinetics 42 (4): 327–360. 2003. doi:10.2165/00003088-200342040-00003. PMID 12648025. 
  5. "Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana". Journal of Analytical Toxicology 16 (5): 276–282. 1992. doi:10.1093/jat/16.5.276. PMID 1338215. 
  6. "Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers". Journal of Analytical Toxicology 33 (8): 469–477. October 2009. doi:10.1093/jat/33.8.469. PMID 19874654. 
  7. 7.0 7.1 "Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules". Frontiers in Pharmacology 13: 956030. 26 August 2022. doi:10.3389/fphar.2022.956030. PMID 36091813. 
  8. "Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity". Molecules 27 (18): 6127. September 2022. doi:10.3390/molecules27186127. PMID 36144858.